Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance
This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients with T790M positive Non-Small Cell Lung Cancer (IIIb / IV ) after Osimertinib resistance.
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
DRUG: Toripalimab + Pemetrexed + Anlotinib
Overall response rate （ORR）, Defined as percentage of participants achieving complete response (CR) and partial response (PR) assessed by the Independent Review Committee (IRC) according to the RECIST 1.1, two years
Progression-free survival (PFS), assessed by IRC and researchers based on RECIST 1.1, two years|Overall survival (OS), assessed by IRC and researchers based on RECIST 1.1, two years|Disease Control Rate (DCR), assessed by IRC and researchers based on RECIST 1.1, two years|Duration of disease response (DOR), assessed by IRC and researchers based on RECIST 1.1, two years|overall incidence of adverse events (AE), overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use., two years
This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients with T790M positive Non-Small Cell Lung Cancer (IIIb / IV ) after Osimertinib resistance.